The risk of developing cancer is increased in IIM patients carrying certain MSAs, such as the anti‐TIF‐1γ Ab, anti‐nuclear matrix protein 2 (NXP2) Ab or anti‐3‐hydroxy‐3‐methylglutaryl‐CoA reductase (HMGCR) Ab. The gene discussed is TRIM33; the disease is cancer.